Role of insulin-like growth factor binding protein 5 in cardiac remodeling after acute myocardial infarction
10.3760/cma.j.cn114656-20250325-00230
- VernacularTitle:急性心肌梗死后胰岛素样生长因子结合蛋白5对心脏重构的作用
- Author:
Jing ZHAO
1
;
Qiming CHEN
;
Tingting HONG
Author Information
1. 浙江大学医学院附属第二医院心内科，杭州 310009
- Keywords:
Insulin-like growth factor binding protein 5;
Acute myocardial infarction;
Cardiac fibrosis;
Cardiac remodeling
- From:
Chinese Journal of Emergency Medicine
2025;34(7):940-944
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the role of insulin-like growth factor binding protein 5 (IGFBP5) in cardiac remodeling following acute myocardial infarction (AMI).Methods:In vivo experiments, a mouse model of AMI was established and randomly divided into three groups: sham-operation group, early AMI group (day 3), and late AMI group (day 28). Western blotting was used to detect the expression of fibrosis-related proteins and IGFBP5 in myocardial tissue. Immunofluorescence staining was performed to assess changes in IGFBP5 expression in the infarcted area at days 3 and 28. Serum IGFBP5 levels were measured using ELISA. In vivo experiments, IGFBP5 expression was silenced in mouse cardiac fibroblasts using siRNA, and the effect on transforming growth factor-β (TGF-β)-induced myofibroblast transdifferentiation was evaluated. One-way ANOVA was used for statistical comparisons among multiple groups.Results:On day 28 after AMI, IGFBP5 expression in myocardial tissue and serum was significantly elevated and positively correlated with the expression of fibrosis markers, including Fibronectin, Periostin, and α-SMA ( P<0.01). Both mouse serum analysis and immunofluorescence staining of heart tissue sections showed that the expression level of IGFBP5 was significantly increased in the late stage of AMI compared to baseline( P<0.001), indicating its potential as a prognostic marker for myocardial infarctionIn vitro, silencing IGFBP5 expression inhibited TGF β-induced fibroblast transdifferentiation and reduced the expression of fibrosis-related proteins ( P<0.05). Conclusion:IGFBP5 may play a role in the progression of AMI and serve as both a potential therapeutic target and a prognostic biomarker.
